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Abstract GNA2132 (Genome-derived Neisseria Antigen
2132) is a surface-exposed lipoprotein discovered by
reverse vaccinology and expressed by genetically diverse
Neisseria meningitidis strains (Pizza et al. 2000). The
protein induces bactericidal antibodies against most strains
of Meningococccus and has been included in a multivalent
recombinant vaccine against N. meningitidis serogroup B.
Structure determination of GNA2132 is important for
understanding the antigenic properties of the protein in
view of increased efﬁciency vaccine development. We
report practically complete
1H,
13C and
15N assignment of
the detectable spectrum of a highly conserved C-terminal
region of GNA2132 (residues 245–427) in micellar solu-
tion, a medium used to improve the spectral quality. The
ﬁrst 32 residues of our construct up to residue 277 were not
visible in the spectrum, presumably because of line
broadening due to solvent and/or conformational exchange.
Secondary structure predictions based on chemical shift
information indicate the presence of an all b-protein with
eight b strands.
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Biological context
Neisseria meningitis is a human pathogen which induces
meningitis and sepsis in children and young adults. The
bacterium is surrounded by a capsular polysaccharide
which deﬁnes thirteen different serogroups, ﬁve of which
(A, B, C, Y, and W135) are the major responsible for
disease in humans (Harrison 2006). Conjugate vaccines
against serogroups A, C, Y and W135 based on polysac-
charides are available or in late phase of development. The
same strategy cannot, however, be used for Meningococcus
B since its capsular polysaccharide has a structural
homology with a polysialic acid [a(2–8)N-acetylneurami-
nic acid], which is present in human cells (Stein et al.
2005). The only vaccines proven to be effective against
serogroup B are based on outer membrane vescicles
(OMV) puriﬁed from the bacterium (Bjune et al. 1991).
The main limitation of such vaccines, also called ‘‘tailor
made’’, is their strain speciﬁcity due to the high variability
of PorA, the main antigenic component of the vesicles
(Stephens 2007).
We have used a genome-based approach, named
‘‘reverse vaccinology’’, to overcome these limitations and
develop a vaccine potentially able to cover the Meningo-
coccus B strain diversity (Pizza et al. 2000). This strategy
has allowed the identiﬁcation of novel surface-exposed
antigens able to induce bactericidal antibodies (Giuliani
et al. 2006), a property known to correlate with protection
in humans. Among this is GNA2132, a surface exposed
lipoprotein of 48 kDa able to induce bactericidal antibodies
and play a protective role in animal models.
Because of its potential importance in vaccinology,
GNA2132 is one of the components of a Meningococcus B
vaccine which has entered phase III clinical trials. Large
effort is being dedicated to the deﬁnition of the structural
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terize its immune response and potential role in patho-
genesis. We have recently shown that GNA2132 is able to
bind heparin through an arginine-rich region and is cleaved
by two different proteases, human lactoferrin and menin-
gococcal NalP (Serruto et al. 2010). Sequence analysis on a
panel of strains representative of the meningococcal
diversity has allowed the deﬁnition of two regions: an
N-terminal domain with several hypervariable regions, and
a C-terminal domain highly conserved in sequence (Pizza
et al. 2000).
As a starting point towards understanding the antigenic
properties of GNA2132 and designing more effective
immunogens, we present here the NMR assignment of the
C-terminal domain of the protein.
Methods and experiment
Expression and puriﬁcation
The region 245-427 of the GNA2132 sequence, cloned in a
pET21b ? vector (Novagen), was expressed in Esche-
richia coli BL21(DE3)-pLysS. The sequence was preceded
by an MA sequence added for cloning reasons and fol-
lowed by a histidine tag (residues LEHHHHHH) for puri-
ﬁcation purposes. Uniformly
15N,
13C-labelled samples were
produced by growing cells at 37C in M9 minimal med-
ium, enriched with 1 g/L
15N-labelled ammonium sulfate
and 4 g/L [U-2H,13C]glucose (Cambridge Isotope Labo-
ratories). The protein was induced with 1 mM isopropyl
b-D-thiogalactopyranoside and expressed for 4 h. The cell
pellet was suspended in 50 mM sodium phosphate buffer at
pH 8 and lysed by lysozyme. The GNA2132 domain was
puriﬁed in two steps by afﬁnity chromatography, using
Ni–NTA and cation exchange columns equilibrated in
50 mM sodium acetate at pH 5.5. Sample purity and
identity were checked by SDS–PAGE and electrospray
mass spectrometry, respectively.
The NMR samples used for assignment typically con-
tained 0.5 mM protein concentrations (95% H2O, 5% D2O)
in 20 mM Tris–HCl, at pH 7, 50 mM NaCl and in the pres-
enceof30 mMdodecyl-phospho-cholate(DPC).Allspectra
were recorded at 40C on a Bruker Avance 700 MHz spec-
trometer equipped with a cryoprobe. Backbone
1HN,
15N,
13Ca,
1Ha,
13C0, and side chain
1H and
13C resonances were
assigned using HSQC, HNCO, HN(CA)CO, HNCA,
HN(CO)CA, CBCANH, CBCA(CO)NH and HNHA
Fig. 1 Quality of the NMR
spectrum and secondary
structure of the C-terminal
domain of GNA2132. a
1H-
15N
HSQC spectrum in 20 mM
Tris–HCl, at pH 7, 50 mM NaCl
and DPC recorded at 40C and
700 MHz proton frequency.
A close up shows the
assignment of the most crowded
region. b Secondary structure
predictions for the sequence of
the GNA2132 domain as
obtained from TALOS? (black
arrows) and from the JPRED
webserver (grey arrows)
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123experiments. HCCH-TOCSY, H(CCCO)NH, CC(CO)NH,
1H-
15N- and
1H-
13C-HSQC-NOESY spectra were also per-
formed for side-chain assignments. Water suppression was
achieved by WATERGATE. Data were processed with
NMRPipe/NMRDraw (Delaglio et al. 1995) and analyzed
with Sparky (Goddard & Kneller, San Francisco, CA).
Torsion angles (u, w) and experimentally based secondary
structurepredictionswere carriedoutfortheHN,Ha,N,Ca,
CbandC0 chemicalshiftsusingTALOS? (Shenetal.2009)
andCSI(WishartandSykes1994)software.Sequencebased
secondary structure predictions were obtained using the
JPRED website (http://www.compbio.dundee.ac.uk/www-
jpred/).
Extent of assignment and data deposition
The GNA2132 domain in aqueous buffer gave rise to well-
resolved 1D NMR spectra, which are typical of a well-
folded species. However, the presence in the
1H-
15N HSQC
spectrum of a number of resonances larger than expected
suggested the presence of more than one species (data not
shown). After initial screening for the best experimental
conditions, we noticed that the spectral quality improved
drastically by the addition of detergents. The additional
species disappeared, for instance, after addition of DPC
and the spectrum became of excellent appearance (Fig. 1a).
This observation could be of relevance for understanding
the functions of the protein in the future.
For the time being, we used DPC for assignment. The
construct used spans residues 244-427 of GNA2132. The
backbone resonances were fully assigned with the excep-
tion of the ﬁrst 32 residues, of M363, K367, F368 and of
the region from Y407 to E413 which could not be identi-
ﬁed in the spectrum. These residues are missing because of
line broadening likely due to solvent exchange and/or
conformational exchange. Of the remaining 142 residues,
more than 94% of the backbone resonances and more than
87% of the side chains resonances were unambiguously
identiﬁed, including the assignment of 90% of the
1H side
chain resonances. Chemical shifts were deposited in the
BioMagResBank under the access number BMRB 16679.
Evaluation of the obtained Ha,C 0,C a and Cb chemical
shifts by TALOS? (Shen et al. 2009) and CSI (Wishart
and Sykes1994) indicates that GNA2132 contains eight
b-strands (residues 276-279, 314-324, 338-346, 350-355
369-376, 388-394, 399-402, 413-418) in reasonable
agreement with sequence structure predictions (Fig. 1b).
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